Atrium Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
RNA$8.23-1.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net loss | $(16,633) | $(7,449) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 151 | 53 |
| Stock-based compensation expense | 12,213 | 1,210 |
| Non-cash operating lease costs | 841 | 56 |
| Changes in operating assets and liabilities: | ||
| Collaboration receivable | (15,000) | — |
| Prepaid and other assets | (1,043) | (928) |
| Other current assets | 1,208 | (2,223) |
| Accounts payable | (3,591) | 37 |
| Accrued liabilities | (1,995) | 542 |
| Accrued compensation | (1,056) | 705 |
| Lease liabilities | (1,029) | (959) |
| Deferred revenues | (4,635) | (1,573) |
| Other long-term liabilities | (574) | (574) |
| Net cash used in operating activities | (31,143) | (11,103) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (2,098) | — |
| Net cash used in investing activities | (2,098) | — |
| Cash flows from financing activities | ||
| Net transfers from Former Parent | 301,505 | 11,103 |
| Net cash provided by financing activities | 301,505 | 11,103 |
| Net increase in cash and cash equivalents | 268,264 | — |
| Cash, cash equivalents and restricted cash, at beginning of period | — | — |
| Cash, cash equivalents and restricted cash, at end of period | $268,264 | $— |
| Reconciliation of cash, cash equivalents and restricted cash, at end of period: | ||
| Cash and cash equivalents | $267,849 | $— |
| Restricted cash included in long-term assets | 415 | — |
| Total cash, cash equivalents and restricted cash | $268,264 | $— |
| Supplemental schedule of noncash investing and financing activities: | ||
| Net assets distributed from Former Parent | $— | $742 |
| Reclassification of deficit from Former Parent | $221,940 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.